27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Persons with dementia were significantly more likely to enter HHC directly from the community (60% vs. 37%, adjusted OR = 1.52, 95% CI = 1.50-1.53). 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The Dementia Datahub (https://dementiadatahub.org/) currently provides mapping, data reporting dashboards, system documentation, and public use files (available upon request) of statistics from the year 2020. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Unmet need for long-term care (LTC) could be associated with higher health care utilization and medical spending. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
This reduction is likely a consequence of the COVID-19 pandemic, which may have decreased overall diagnostic opportunities. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Donanemab increased total healthcare costs ($300,689 vs. $178,121) and societal costs ($389,113 vs. $283,618) compared with standard care per capita, while improving health outcomes (4.38 vs. 4.01 QALYs) per capita. 5 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Microglia are central regulators of Alzheimer's disease pathogenesis, but their roles cannot be reduced to a simple protective-versus-harmful dichotomy. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
In this update, we discuss the use of real-world data in the Haute Autorité de Santé assessment of economic evaluations, review how real-world evidence is supporting regulatory approvals in multiple myeloma, and consider lessons from the failed EVOKE trials of semaglutide in Alzheimer's disease for the broader application of target trial emulation. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Dementias are expensive diseases: the net annual cost in European healthcare is about € 28.000 per case with a strong stage dependency, of which medical care accounts for about 19%. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Home-visit nursing can reduce early readmissions and improve quality of life in older patients with heart failure (HF). 5 key findings →
Participants: 88 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Enrollment in an MA plan is associated with a higher probability of AWV uptake, particularly among vulnerable populations from racial and ethnic minorities, dual eligibility, and those diagnosed with ADRD. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The 5' untranslated region (UTR) of the APP gene, encompassing 147 base pairs between the transcriptional (+1) and the translational start site, was examined for its role in APP expression. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
= 314,472) as early OAC initiation. Median age for both cohorts was 78 years. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
ADRD specialist and drug utilization is relatively low in both DS and non‐DS, with no significant R/E differences. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
We found significant county-level variability in utilization of high-quality home health. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Medicare Help at Home—a proposal to add supplemental home- and community-based services—could be financed by income-related cost-sharing, beneficiary monthly premiums of $42, and an incremental payroll tax on employers and employees of 0.4 percent. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Among Medicare beneficiaries from 2008 to 2018, AD incidence generally decreased while MCI increased. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
A targeted HCBS benefit could be added to Medicare and financed with income-related cost sharing ranging from 5% to 50%, a premium paid by Medicare beneficiaries of approximately $42 a month, and payroll taxes estimated at around 0.4% of earnings on employers and employees. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Our study underscores the role of telehealth in increasing AWV uptake and facilitating cognitive assessments. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Patient access to innovative care for complex conditions like schizophrenia remains limited by systemic, clinical and policy-level barriers. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
ADRD mortality rates were slightly higher in rural areas compared to urban areas, with no significant differences between rural-adjacent and rural-nonadjacent counties in recent years. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Advance Care Planning (ACP) is a continuous process that enables individuals to discuss and document their preferences for future care in the event of terminal illness or incapacitation. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
MA-PD enrollees had significantly lower utilization of PIMs than standalone PDP enrollees: a 0.7 percentage-point [95% CI: 0.5, 0.8] lower prevalence of potentially harmful drug-disease interactions in older adults with dementia; a 3.1 percentage-point [2.6, 3.5] lower prevalence of potentially harmful drug-disease interactions in older adults with dementia and a history of falls; and a 0.5 percentage-point [0.4, 0.6] lower prevalence of high-risk medications in older adults. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Leveraging real-world data to better understand health care utilization patterns prior to and after incident AD diagnosis may help inform the clinical management of the disease. 1 key finding →
Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Analysis of the use of hypnotic medication versus CBT for insomnia using an established model for ethical medical decision making leads to the conclusion that hypnotics are not appropriate as the initial treatment in cases of chronic insomnia. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Medicare enrollment among people with Alzheimer’s Disease and Related Dementias (ADRD) has reached an all-time high with about 12% of beneficiaries having an ADRD diagnosis. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →